Thailand Diabetes Drugs and Devices Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 0.28 Billion |
| Market Size (2029) | USD 0.35 Billion |
| CAGR (2024 - 2029) | > 5.02 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Thailand Diabetes Drugs and Devices Market Analysis
The Thailand Diabetes Drugs And Devices Market size is estimated at USD 0.28 billion in 2024, and is expected to reach USD 0.35 billion by 2029, growing at a CAGR of greater than 5.02% during the forecast period (2024-2029).
Healthcare systems have been significantly disrupted and strained at every stage of the rapid spread of COVID-19. Several countries, notably the Thai government, have implemented home quarantine or home isolation programs to prevent medical collapse and improve inadequate medical resources. The number of people infected with COVID-19 in hospitals has increased. Previous studies have shown that telemedicine-based COVID-19 home monitoring programs are feasible in several countries to fill treatment gaps during health worker shortages. These programs monitored symptom intensity and informed patients to seek additional treatment if needed. During the COVID-19 epidemic, hospital capacity was insufficient, and a home isolation system was introduced.
The Thai government has launched education and support on Diabetes Self-Management (DSMES) and telemedicine glycemic control, along with outcomes for COVID-19 patients who have been quarantined at home. In August 2022, the National Research Council of Thailand (NRCT) unveiled a prototype of a Breathalyzer detector that can detect people infected with the new coronavirus with 97% accuracy.
The Thai government has provided medical supplies such as blood glucose meters, blood glucose test strips, lancets and urine test strips donated or purchased with donations during the COVID-19 crisis. Supplies were stored in a central location and distributed by volunteers using same-day commercial delivery services. Pre-filled disposable insulin pens, both long-acting and short-acting analogues, have been chosen instead of insulin vials to reduce dosing errors, especially in insulin patients. Insulin pens were stored at the clinic and distributed by same-day delivery service in temperature-controlled containers.
Thus, the above factors are expected to drive market growth over the forecast period.
Thailand Diabetes Drugs and Devices Market Trends
The continuous Glucose Monitoring Segment is Expected to Witness the Highest Growth Rate Over the Forecast Period
The continuous glucose monitoring segment is expected to register a CAGR of more than 11% over the forecast period.
A continuous blood glucose monitor is a new technology blood glucose monitor that monitors blood glucose levels day and night. Sensors: Sensors are disposable devices placed under the skin to measure blood sugar levels. The sensor can be used for several days before needing replacement. A ruggedized device consists of a transmitter and a receiver. The transmitter is connected to the sensor, and the reader (receiver) receives and displays the readings. This device provides real-time measurements. This sensor device is a small electrode that measures the blood sugar level of people with diabetes.
The sensor continuously measures glucose levels in the body through tiny threads inserted under the skin and records glucose levels. Within 5 seconds, the user can download the data stored in the sensor. The Indian continuous blood glucose monitoring device market considers the FreeStyle Libre Pro sensor (14-day run), Dexcom's G4 sensor (10-day run), Medtronic's Guardian sensor (7-day run), and fluorescence sensors.
The introduction of low-cost CGM in the next few years and government support through subsidies for diabetes monitoring devices may allow CGM device makers to enter the promising Thailand market.
Rising diabetes prevalence in Thailand driving the market in the forecast year
The World Health Organization (WHO) stated that diabetes care accounted for about 11% of Thailand's total healthcare expenditure in 2022, a figure on par with other countries in the region. By 2030, that number is projected to grow by 41%, effectively doubling the social burden of diabetes. There are only 272 endocrinologists (specialists) in Thailand. In Thailand, 3 out of 5 of her diabetics on treatment do not meet recommended treatment goals. According to the WHO report, the five countries most likely to suffer from diabetes include Indonesia, China, India, Brazil, and the United States.
Thailand is facing an increase in diabetes due to lifestyle changes, leading to a rise in obesity. Lack of exercise and unhealthy diets are more common in Thailand's urban areas. The Thai government is trying to combat the threat of diabetes through programs such as the Thailand Healthy Lifestyle Strategic Plan 2011-2020. Such programs help people with diabetes understand the benefits of the various diabetes devices.
Diabetes is one of the world's major health problems today, and its prevalence is steadily increasing. According to the World Diabetes Federation, 450 million people worldwide already have diabetes, which is expected to reach 642 million by 2041. Asian countries account for more than 60% of diabetics worldwide2. In addition, compared to other races, Asians may be more prone to type 2 diabetes and at higher risk of diabetic complications.
Blood pressure control is an important part of diabetes management. In addition, people with diabetes are often recommended certain antihypertensive drugs to protect against kidney and heart complications, even if they do not have high blood pressure. No scientific evidence links these antihypertensive drugs to the likelihood or effects of COVID-19 infection. Hyperglycemia (hyperglycemia) is a symptom of diabetes caused by a lack of insulin hormones, problems with insulin secretion, or both.
High blood sugar can cause vital organs to malfunction, deteriorate, and be destroyed. Changing and non-changing variables can contribute to uncontrolled blood sugar levels. Gender, age, duration of diabetes, micro- and macrovascular complications, and comorbidities are immutable factors. Examples of reversible factors include behavioral and psychosocial problems such as poor eating habits, lack of exercise, obesity, not taking prescribed medications as prescribed by a doctor, stress, sadness, anxiety, and especially diabetes-Related concerns, etc.
The increasing diabetes prevalence and the above factors will likely drive segment growth over the forecast period.
Thailand Diabetes Drugs and Devices Industry Overview
Novo Nordisk partnered with Abbott Diabetes Care, which may also assist to enable insulin statistics to be shared between Novo Nordisk-connected insulin pens and digital fitness equipment well suited to the FreeStyle Libre portfolio of products.
Thailand Diabetes Drugs and Devices Market Leaders
-
Medtronics
-
Roche
-
NovoNordisk
-
Sanofi
-
Omnipod
*Disclaimer: Major Players sorted in no particular order
Thailand Diabetes Drugs and Devices Market News
- August 2023: The successful bid for hosting the "IDF World Diabetes Congress 2025" in Bangkok was announced at a press conference organized by the International Diabetes Federation (IDF), in collaboration with the Diabetes Association of Thailand, the Ministry of Public Health, the Bangkok Metropolitan Administration, and the Thailand Convention and Exhibition Bureau (TCEB).
- April 2022: The insulin pen has been approved by the Thailand Food and Drug Administration (TFDA) through the cooperation between Gan & Lee Thai partner and Gan & Lee. The approved Insulin Pen can be used with the Gan & Lee 3mL cartridge insulin penfill. By adjusting the dose knob, patients can set 1-60 units (U) of insulin for administration. The minimum scale of the pen is accurate to 1 unit (U), which can meet the needs of diabetic patients for daily injections.
Thailand Diabetes Drugs And Devices Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.3 \Porter's Five Forces Analysis
4.3.1 Bargaining Power of Suppliers
4.3.2 Bargaining Power of Consumers
4.3.3 Threat of New Entrants
4.3.4 Threat of Substitute Products and Services
4.3.5 Intensity of Competitive Rivalry
5. Market Segmentation (Market Size by Value - USD)
5.1 Devices
5.1.1 Monitoring Devices
5.1.1.1 Self-monitoring Blood Glucose Devices
5.1.1.2 Continuous Blood Glucose Monitoring
5.1.2 Management Devices
5.1.2.1 Insulin Pump
5.1.2.2 Insulin Syringes
5.1.2.3 Insulin Cartridges
5.1.2.4 Disposable Pens
5.2 Drugs
5.2.1 Oral Anti-Diabetes Drugs
5.2.2 Insulin Drugs
5.2.3 Combination Drugs
5.2.4 Non-Insulin Injectable Drugs
6. Market Indicators
6.1 Type-1 Diabetes Population
6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
7.1 Company Profiles
7.1.1 Novo Nordisk
7.1.2 Medtronic
7.1.3 Insulet
7.1.4 Tandem
7.1.5 Ypsomed
7.1.6 Novartis
7.1.7 Sanofi
7.1.8 Eli Lilly
7.1.9 Abbottt
7.1.10 Roche
7.1.11 Astrazeneca
7.1.12 Dexcom
7.1.13 Pfizer
- *List Not Exhaustive
7.2 Company Share Analysis
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
Thailand Diabetes Drugs and Devices Industry Segmentation
Patients with type 1 diabetes must be given insulin because their pancreas cannot process it. To control blood sugar levels, insulin must be given several times daily, such as when eating or drinking. Many people with type 2 diabetes also need to take antidiabetic drugs. These drugs include diabetes medications and injections such as insulin. Thailand's diabetes drugs and devices market is segmented by drugs (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs) and devices (management devices (insulin pumps, insulin pens, syringes, cartridges, and jet injectors) and monitoring devices (self-monitoring blood and continuous glucose monitoring)). The report offers the value (in USD) and volume (in Unit) for the above segments.
| Devices | ||||||
| ||||||
|
| Drugs | |
| Oral Anti-Diabetes Drugs | |
| Insulin Drugs | |
| Combination Drugs | |
| Non-Insulin Injectable Drugs |
Thailand Diabetes Drugs And Devices Market Research Faqs
How big is the Thailand Diabetes Drugs And Devices Market?
The Thailand Diabetes Drugs And Devices Market size is expected to reach USD 0.28 billion in 2024 and grow at a CAGR of greater than 5.02% to reach USD 0.35 billion by 2029.
What is the current Thailand Diabetes Drugs And Devices Market size?
In 2024, the Thailand Diabetes Drugs And Devices Market size is expected to reach USD 0.28 billion.
Who are the key players in Thailand Diabetes Drugs And Devices Market?
Medtronics, Roche, NovoNordisk, Sanofi and Omnipod are the major companies operating in the Thailand Diabetes Drugs And Devices Market.
What years does this Thailand Diabetes Drugs And Devices Market cover, and what was the market size in 2023?
In 2023, the Thailand Diabetes Drugs And Devices Market size was estimated at USD 0.27 billion. The report covers the Thailand Diabetes Drugs And Devices Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Thailand Diabetes Drugs And Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Thailand Diabetes Drugs And Devices Industry Report
Statistics for the 2024 Thailand Diabetes Drugs and Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Thailand Diabetes Drugs and Devices analysis includes a market forecast outlook to for 2024 to 2029) and historical overview. Get a sample of this industry analysis as a free report PDF download.
